
Amitkumar Mehta, MD, details the FDA approval of tafasitamab with rituximab and lenalidomide for relapsed/refractory follicular lymphoma.

Your AI-Trained Oncology Knowledge Connection!


Amitkumar Mehta, MD, details the FDA approval of tafasitamab with rituximab and lenalidomide for relapsed/refractory follicular lymphoma.




















Published: February 26th 2021 | Updated:

Published: February 19th 2021 | Updated:

Published: March 12th 2021 | Updated:

Published: February 12th 2021 | Updated:

Published: March 26th 2021 | Updated:

Published: March 19th 2021 | Updated: